Real-World Semaglutide Use Linked to Lower Liver Stiffness, With Benefits Beyond Weight Loss

Semaglutide use was associated with reduced liver stiffness and lower rates of several liver-related outcomes among patients with preexisting liver disease, although the relationships differed according to attained dose and degree of weight loss, according to findings published in npj Gut and Liver.¹ The real-world study expands on clinical trial evidence supporting semaglutide for metabolic dysfunction-associated steatohepatitis (MASH), but its uncontrolled, retrospective design prevents conclusions that semaglutide directly caused the observed improvements.

In a longitudinal cohort of 326 adults with elastography measurements before and after semaglutide initiation, median liver stiffness declined from 4.85 kPa to 3.9 kPa. Overall, approximately 59.5% of patients had lower stiffness after treatment, 40.8% achieved a reduction of at least 20%, and 21.2% moved to a lower elastography-defined fibrosis stage.¹

The findings are clinically relevant because fibrosis severity is a major predictor of liver-related complications and mortality in metabolic dysfunction-associated steatotic liver disease (MASLD).¹ Semaglutide (Wegovy; Novo Nordisk) received accelerated FDA approval in August 2025 for adults with noncirrhotic MASH and moderate-to-advanced fibrosis, consistent with stages F2 to F3.² The approval was supported by interim findings from the phase 3 ESSENCE trial (NCT04822181), in which semaglutide significantly improved MASH resolution and fibrosis outcomes compared with placebo.^2,3 The approved maintenance dosage for MASH is 2.4 mg once weekly, with a reduction to 1.7 mg permitted when the higher dosage is not tolerated.⁴

Higher Semaglutide Dose Was Associated With Lower Risk of Select Outcomes

Researchers analyzed deidentified data from the nSights Federated electronic health record (EHR) Network, identifying 269,390 patients who initiated semaglutide between March 2018 and January 2024. Among these patients, 6734 had preexisting liver disease, and 6051 met the eligibility criteria for the dose-based landmark analysis.¹

During the first 2 years following semaglutide initiation, 4218 patients attained a maximum dose ranging from 0.25 to 1.0 mg, whereas 1833 reached a maximum dose of at least 1.7 mg. Increasing dose was associated with progressively greater weight reduction across the evaluated dose range, with each 1-mg increase corresponding to an estimated 3.08% greater maximum weight loss. Researchers subsequently assessed liver-related outcomes over the following 2 years among patients without the respective outcome at the start of follow-up.¹

Higher-dose semaglutide was associated with a lower 2-year incidence of steatohepatitis compared with lower-dose treatment (3.5% vs 5.5%; relative risk [RR], 0.64; P = .026). The incidence of alcohol-associated liver disease was also lower in the higher-dose group (0.8% vs 1.7%; RR, 0.48; P = .025), and higher-dose treatment was associated with a lower absolute rate of all-cause mortality.¹

However, time-to-event analyses did not demonstrate statistically significant differences between the dose groups for alcohol-associated liver disease or all-cause mortality. Additionally, none of the other 17 evaluated outcomes—including cirrhosis, portal hypertension, hepatic decompensation, and hepatocellular carcinoma—differed significantly according to attained dose.¹ These findings suggest that higher semaglutide exposure may offer benefits across selected hepatic outcomes, although prospective controlled studies are needed to confirm the observed associations and determine whether they reflect a causal dose-response relationship.

Weight Loss and Dose Showed Different Liver-Benefit Patterns

In the weight-based analysis, patients were grouped according to the maximum weight reduction achieved during the initial 2-year period: less than 5%, 5% to 10%, 10% to 15%, 15% to 20%, or at least 20%. Greater weight reduction was associated with lower subsequent risk of steatohepatitis and steatotic liver disease, although the steatohepatitis relationship was not consistently linear across every category.¹

Hepatorenal syndrome also differed across weight-loss strata, but the investigators cautioned that the number of events was small. The remaining evaluated outcomes did not vary significantly according to the magnitude of weight loss.¹

These patterns suggest that treatment intensity and weight reduction may relate differently to individual hepatic outcomes. Greater weight loss appeared most closely associated with lower risks of steatotic and inflammatory liver disease, whereas attained semaglutide dose produced a separate signal involving steatohepatitis, alcohol-associated liver disease, and mortality.¹

Liver Stiffness Improved Most in Patients With Greater Baseline Disease Severity

The complementary elastography analysis included 326 semaglutide-treated adults with a quantitative liver stiffness measurement obtained up to 5 years before treatment and another measurement between 6 months and 5 years after initiation. The mean age was about 53.8 years, approximately 56.7% were women, 64.1% had type 2 diabetes, 77.9% had obesity, and 69.0% had a recorded MASLD-related diagnosis.¹

Median liver stiffness decreased by about 0.38 kPa across the overall cohort (P < .001). Of the 326 patients, 194 had lower stiffness at follow-up, 121 had higher stiffness, and 11 had no change. Elastography-defined stage regression occurred in 69 patients, compared with stage progression in 30 patients.¹

Improvement was concentrated among patients with greater baseline stiffness. A reduction of at least 20% was achieved by 29.5% of patients with baseline stiffness below 7 kPa, compared with 56.4% of those between 7 and 9.5 kPa, 78.3% of those between 9.5 and 12.5 kPa, and 80.0% of those with cirrhosis-range measurements of at least 12.5 kPa. Among 92 patients who began in the F2 through F4 ranges, 58 (63.0%) were classified in the F0 to F1 range at follow-up.¹

Liver stiffness is not interchangeable with biopsy-confirmed fibrosis, however. Elastography measurements can also be affected by inflammation, congestion, cholestasis, steatosis, and technical or modality-related factors.¹

Stiffness Changes Were Not Explained by Weight Loss Alone

Among 250 patients with repeated weight measurements, median weight declined by 4.85 kg and body mass index declined by 1.80 kg/m². Nevertheless, weight change had essentially no correlation with liver stiffness change (Pearson r= 0.017; P = .79). Approximately 40% of patients who lost at least 10% of their body weight achieved a 20% or greater stiffness reduction, as did approximately 40% of patients who lost no weight or gained weight.¹

Semaglutide was also associated with mean reductions in glycated hemoglobin of 0.81 percentage points, alanine aminotransferase of 9.93 U/L, and aspartate aminotransferase of 4.99 U/L. None of these changes correlated meaningfully with the reduction in liver stiffness.¹

The investigators stressed that this disconnect does not establish a direct, weight-independent hepatic effect. Incomplete weight measurements, changes in visceral fat not reflected by total body weight, selective follow-up, regression to the mean, and residual confounding could all have contributed. Single-cell RNA-sequencing also showed extremely sparse hepatic glucagon-like peptide (GLP)-1 receptor expression, including minimal expression in hepatocytes, leaving the mechanism of any potential direct liver effect unresolved.¹

Findings Add Real-World Context to the ESSENCE Trial

The results complement the phase 3 ESSENCE trial, in which 63% of patients receiving semaglutide 2.4 mg achieved MASH resolution without worsening fibrosis at week 72, compared with 34% receiving placebo. Fibrosis improvement without worsening MASH occurred in 37% and 22% of patients, respectively.³ These findings supported the accelerated FDA approval of semaglutide for noncirrhotic MASH with F2 to F3 fibrosis and subsequent updates to American Association for the Study of Liver Diseases practice guidance.^2,5

Unlike ESSENCE, the new analysis did not include an untreated or active-comparator control group, did not confirm medication adherence or persistence, and did not adjust the reported comparisons for differences in baseline clinical characteristics. The serial-elastography cohort was also highly selected and had substantially more baseline cirrhosis than the broader outcome cohort. Additionally, numerous outcomes and patient strata were evaluated using nominal P values without correction for multiple comparisons, increasing the possibility of false-positive findings.¹

For pharmacists, the study reinforces the importance of supporting appropriate semaglutide titration, adherence, adverse effect management, and longitudinal metabolic and hepatic monitoring. However, the findings should not be used to expand treatment beyond the approved MASH population or to interpret liver stiffness improvement as confirmed fibrosis regression. Prospective controlled studies with relevant comparators and standardized elastography or histologic assessments are needed to determine whether the observed improvements reflect semaglutide exposure, weight reduction, other systemic effects, or differences among patients able to remain on higher doses.

REFERENCES

1. Venkatakrishnan, A.J., Purushotham, K., Varma, G. et al. Semaglutide is associated with stiffness improvement and broad liver benefits with distinct dose- and weight-linked patterns. npj Gut Liver 3, 28 (2026). doi:10.1038/s44355-026-00076-w

2. FDA approves treatment for serious liver disease known as “MASH.” FDA. News release. August 15, 2025. Accessed August 6, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash

3. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. doi:10.1056/NEJMoa2413258

4. Wegovy prescribing information. Novo Nordisk; 2025. Accessed Augut 6, 2026. https://www.novo-pi.com/wegovy.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf

5. Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, Allen AM. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2026;83(5):1326-1340. doi:10.1097/HEP.0000000000001608